153 related articles for article (PubMed ID: 9592201)
1. The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) and vinblastine combined with interferon in nude mice xenografts of human renal cell carcinoma.
Rohde D; Goertz M; Blatter J; Jakse G
Int J Oncol; 1998 Jun; 12(6):1367-72. PubMed ID: 9592201
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines.
Rohde D; Hayn HK; Blatter J; Jakse G
Int J Oncol; 1998 Jun; 12(6):1361-6. PubMed ID: 9592200
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha and gemcitabine (2',2'-difluorodeoxycytidine) in adult and pediatric renal tumors.
Rohde D; Goertz M; Hayn H; Cremer U; Jakse G
Int J Oncol; 1997 Sep; 11(3):623-7. PubMed ID: 21528256
[TBL] [Abstract][Full Text] [Related]
4. Experimental and clinical efficacy of 2', 2'-difluorodeoxycytidine (gemcitabine) against renal cell carcinoma.
Rohde D; De Mulder PH; Weissbach L; Osieka R; Blatter J; Jakse G
Oncology; 1996; 53(6):476-81. PubMed ID: 8960143
[TBL] [Abstract][Full Text] [Related]
5. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
6. Treatment with tumor necrosis factor alpha and interferon alpha of a human kidney cancer xenograft in nude mice: evidence for an anticachectic effect of interferon alpha.
Bassukas ID; Hofmockel G; Maurer-Schultze B
Anticancer Res; 1994; 14(1A):237-45. PubMed ID: 8166454
[TBL] [Abstract][Full Text] [Related]
7. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice.
Solorzano CC; Hwang R; Baker CH; Bucana CD; Pisters PW; Evans DB; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 May; 9(5):1858-67. PubMed ID: 12738744
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
9. [Antiproliferative effect of interferon-alpha on human renal cell carcinoma in clonogenic assay--single and combination effect with cancer chemotherapeutic agent].
Ohmura K; Tsukamoto T
Hinyokika Kiyo; 1989 May; 35(5):737-47. PubMed ID: 2801371
[TBL] [Abstract][Full Text] [Related]
10. Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388.
Marañda E; Szmigielska A; Robak T
Cancer Invest; 1999; 17(2):95-101. PubMed ID: 10071592
[TBL] [Abstract][Full Text] [Related]
11. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
12. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
13. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma.
Perez-Zincer F; Olencki T; Budd GT; Peereboom D; Elson P; Bukowski RM
Invest New Drugs; 2002 Aug; 20(3):305-10. PubMed ID: 12211213
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein.
Nanus DM; Pfeffer LM; Bander NH; Bahri S; Albino AP
Cancer Res; 1990 Jul; 50(14):4190-4. PubMed ID: 2364374
[TBL] [Abstract][Full Text] [Related]
16. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts.
van Dijk J; Uemura H; Beniers AJ; Peelen WP; Zegveld ST; Fleuren GJ; Warnaar SO; Oosterwijk E
Int J Cancer; 1994 Jan; 56(2):262-8. PubMed ID: 8314310
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft.
El-Galley R; Keane TE; Sun C
Urol Oncol; 2003; 21(1):49-57. PubMed ID: 12684128
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
Tsavaris N; Skarlos D; Bacoyiannis C; Aravantinos G; Kosmas C; Retalis G; Panopoulos C; Vadiaka M; Dimitrakopoulos A; Kostantinidis K; Mitropoulos D; Bougas D; Pantazopoulos D; Kosmidis P
J Interferon Cytokine Res; 2000 Aug; 20(8):685-90. PubMed ID: 10954911
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma.
Kriegmair M; Oberneder R; Hofstetter A
Urology; 1995 May; 45(5):758-62. PubMed ID: 7747370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
